Clinical Trials Directory

Trials / Completed

CompletedNCT02048176

Posterior Fossa Mutism on Quality of Life

Long-Term Impact of Posterior Fossa Mutism on Quality of Life

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago · Academic / Other
Sex
All
Age
8 Years – 25 Years
Healthy volunteers
Not accepted

Summary

Posterior fossa mutism (PFM) occurs in up to 30% of patients after resection of a posterior fossa tumor, most commonly a medulloblastoma. PFM is characterized by delayed onset of mutism 1-6 days after surgery that can spontaneously improve on average from 7-8 weeks later. Few patients recover normal speech. Most of their speech continues to be marked by dysarthria, dysfluency and slowed rate. Researchers have not identified the pathophysiologic mechanism for PFM nor have they found a cure. Despite the improvements in speech, patients with PFM have shown multiple areas of neurocognitive deficits 12 months after diagnosis. Few studies have looked at long term outcomes of patients affected by PFM. We propose to survey patients who developed PFM after resection of a medulloblastoma to determine long term effects of PFM on patient's quality of life.

Conditions

Timeline

Start date
2011-07-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2014-01-29
Last updated
2024-08-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02048176. Inclusion in this directory is not an endorsement.

Posterior Fossa Mutism on Quality of Life (NCT02048176) · Clinical Trials Directory